Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Clinical Activity
100%
Carfilzomib
100%
Pharmacodynamic Assay
100%
Proteasome Subunits
100%
Occupancy
80%
Immunoproteasome Subunits
60%
Protease Inhibitors
40%
Enzyme-linked Immunosorbent Assay (ELISA)
40%
Peripheral Blood Mononuclear Cells
40%
Proteasome Inhibition
40%
High Dose
20%
Clinical Trials
20%
Clinical Response
20%
Active Sites
20%
Effective Tool
20%
Multiple Myeloma
20%
CD138
20%
Tumor Cells
20%
Near-complete
20%
Patient Outcomes
20%
Therapeutic Approaches
20%
Drug Action
20%
Whole Blood
20%
Patient Response
20%
Complete Recovery
20%
Chymotrypsin
20%
Multiple Myeloma Patients
20%
Inhibitor Activity
20%
Five-phase
20%
Inhibition Profiles
20%
Immunoproteasome
20%
Constitutive Proteasome
20%
Dose-dependent
20%
Enzyme-Linked Immunosorbent
20%
Pharmacology, Toxicology and Pharmaceutical Science
Pharmacodynamics
100%
Proteasome
100%
Carfilzomib
100%
Proteasome Inhibitor
25%
Enzyme-Linked Immunosorbent Assay
25%
Multiple Myeloma
25%
Clinical Trial
12%
Chymotrypsin
12%
Drug Action
12%
Enzymes
12%
Biochemistry, Genetics and Molecular Biology
Proteasome
100%
Pharmacodynamics
100%
Enzyme Subunit
37%
Peripheral Blood Mononuclear Cell
25%
Proteasome Inhibitor
25%
Drug Megadose
12%
Clinical Trial
12%
Active Site
12%
Drug Mechanism
12%
Chymotrypsin
12%
Immunology and Microbiology
Proteasome
100%
Pharmacodynamics
100%
Multiple Myeloma
20%
Enzyme-Linked Immunosorbent Assay
20%
Peripheral Blood Mononuclear Cell
20%
Drug Megadose
10%
Tumor Cell
10%
Drug Mechanism
10%
Enzyme Subunit
10%